AVEO AVEO Pharmaceuticals Inc.

3.07
+0.02  (1%)
Previous Close 3.05
Open 3.04
Price To book -19.19
Market Cap 363205007
Shares 118,307,820
Volume 2,302,351
Short Ratio 1.90
Av. Daily Volume 5,382,058

SEC filingsSee all SEC filings

  1. 8-K - Current report 171039132
  2. 8-K - Current report 171021899
  3. 8-K - Current report 171016555
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016383
  5. 8-K - Current report 17932710

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiation of dosing announced March 22, 2017. Phase 2 part of trial initiation announced June 9, 2017.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
Ficlatuzumab
EGFR-mutated Non-small cell lung cancer (NSCLC)
Phase 3 completion of enrollment noted June 20, 2017. Futility analysis released October 6, 2017 - trial to continue as planned. Top-line data due 1Q 2018.
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer

Latest News

  1. AVEO Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AVEO) : October 18, 2017
  2. Here's Why AVEO Pharmaceuticals Dropped as Much as 16.3% Today
  3. AVEO Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AVEO-US : October 17, 2017
  4. AVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium
  5. Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Novavax
  6. Featured Company News - AVEO Declares Completion of TIVO-3 Study Futility Analysis
  7. AVEO Oncology Announces Completion of TIVO-3 Study Futility Analysis with No Changes to Study Protocol
  8. Two Techs And Two Biotechs Breaking Out
  9. Harry Boxer’s four stocks that are breaking out this week
  10. ETFs with exposure to AVEO Pharmaceuticals, Inc. : September 26, 2017
  11. AVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in
  12. Should You Have AVEO Pharmaceuticals Inc’s (AVEO) In Your Portfolio?
  13. AVEO Oncology Announces Receipt of Payments from EUSA Pharma and CANbridge
  14. Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.
  15. AVEO Oncology to Present at Upcoming Conferences
  16. Featured Company News - AVEO Pharma's FOTIVDA(R) Licensed in EU for the Treatment of Advanced Renal Cell Carcinoma
  17. AVEO Pharma stock rises 6% after cancer drug gets approved in Europe
  18. AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma
  19. ETFs with exposure to AVEO Pharmaceuticals, Inc. : August 25, 2017

SEC Filings

  1. 8-K - Current report 171039132
  2. 8-K - Current report 171021899
  3. 8-K - Current report 171016555
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016383
  5. 8-K - Current report 17932710
  6. 8-K - Current report 17926406
  7. CT ORDER - Confidential treatment order 17883801
  8. CT ORDER - Confidential treatment order 17876509
  9. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17851760
  10. 8-K - Current report 17851741